These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 33438008)

  • 1. Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study.
    Sandborn WJ; Feagan BG; Hanauer S; Vermeire S; Ghosh S; Liu WJ; Petersen A; Charles L; Huang V; Usiskin K; Wolf DC; D'Haens G
    J Crohns Colitis; 2021 Jul; 15(7):1120-1129. PubMed ID: 33438008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Approximately 3 Years of Continuous Ozanimod in Moderately to Severely Active Ulcerative Colitis: Interim Analysis of the True North Open-label Extension.
    Danese S; Panaccione R; Abreu MT; Rubin DT; Ghosh S; Dignass A; Afzali A; Wolf DC; Chiorean MV; Vermeire S; Jain A; Charles L; Lawlor G; Osterman MT; Wu H; Canavan JB; Petersen A; Colombel JF; Regueiro M
    J Crohns Colitis; 2024 Feb; 18(2):264-274. PubMed ID: 37651686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis.
    Sandborn WJ; Feagan BG; D'Haens G; Wolf DC; Jovanovic I; Hanauer SB; Ghosh S; Petersen A; Hua SY; Lee JH; Charles L; Chitkara D; Usiskin K; Colombel JF; Laine L; Danese S;
    N Engl J Med; 2021 Sep; 385(14):1280-1291. PubMed ID: 34587385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular Safety of Ozanimod in Patients With Ulcerative Colitis: True North and Open-Label Extension Analyses.
    Armuzzi A; Cross RK; Lichtenstein GR; Hou J; Deepak P; Regueiro M; Wolf DC; Akukwe L; Ahmad HA; Jain A; Kozinn M; Wu H; Petersen A; Charles L; Long M
    Clin Gastroenterol Hepatol; 2024 May; 22(5):1067-1076.e3. PubMed ID: 38040274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ozanimod: A Review in Ulcerative Colitis.
    Paik J
    Drugs; 2022 Aug; 82(12):1303-1313. PubMed ID: 35994200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis.
    Sandborn WJ; Feagan BG; Wolf DC; D'Haens G; Vermeire S; Hanauer SB; Ghosh S; Smith H; Cravets M; Frohna PA; Aranda R; Gujrathi S; Olson A;
    N Engl J Med; 2016 May; 374(18):1754-62. PubMed ID: 27144850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Achievement of Clinical, Endoscopic, and Histological Outcomes in Patients with Ulcerative Colitis Treated with Etrasimod, and Association with Faecal Calprotectin and C-reactive Protein: Results From the Phase 2 OASIS Trial.
    Yarur AJ; Chiorean MV; Panés J; Jairath V; Zhang J; Rabbat CJ; Sandborn WJ; Vermeire S; Peyrin-Biroulet L
    J Crohns Colitis; 2024 Jun; 18(6):885-894. PubMed ID: 38245818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ozanimod as a novel oral small molecule therapy for the treatment of Crohn's disease: The YELLOWSTONE clinical trial program.
    Feagan BG; Schreiber S; Afzali A; Rieder F; Hyams J; Kollengode K; Pearlman J; Son V; Marta C; Wolf DC; D'Haens GG
    Contemp Clin Trials; 2022 Nov; 122():106958. PubMed ID: 36208720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ozanimod in Patients With Moderate to Severe Ulcerative Colitis Naive to Advanced Therapies.
    Sands BE; D'Haens G; Panaccione R; Regueiro M; Ghosh S; Hudesman D; Ahmad HA; Mehra D; Wu H; Jain A; Petersen A; Osterman MT; Afzali A; Danese S
    Clin Gastroenterol Hepatol; 2024 May; ():. PubMed ID: 38723981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real World Clinical Effectiveness and Safety of Ozanimod in the Treatment of Ulcerative Colitis: 1-Year Follow-Up from a Tertiary Center.
    Cohen NA; Choi D; Garcia N; Choi NK; Picker E; Krugliak Cleveland N; Cohen RD; Dalal SR; Pekow J; Rubin DT
    Dig Dis Sci; 2024 Feb; 69(2):579-587. PubMed ID: 38087126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study.
    Feagan BG; Sandborn WJ; Danese S; Wolf DC; Liu WJ; Hua SY; Minton N; Olson A; D'Haens G
    Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):819-828. PubMed ID: 32553149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term Safety and Efficacy of Etrasimod for Ulcerative Colitis: Results from the Open-label Extension of the OASIS Study.
    Vermeire S; Chiorean M; Panés J; Peyrin-Biroulet L; Zhang J; Sands BE; Lazin K; Klassen P; Naik SU; Cabell CH; Sandborn WJ
    J Crohns Colitis; 2021 Jun; 15(6):950-959. PubMed ID: 33475734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: Data from ULTRA 1, 2, and 3.
    Colombel JF; Sandborn WJ; Ghosh S; Wolf DC; Panaccione R; Feagan B; Reinisch W; Robinson AM; Lazar A; Kron M; Huang B; Skup M; Thakkar RB
    Am J Gastroenterol; 2014 Nov; 109(11):1771-80. PubMed ID: 25155227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ozanimod: A First-in-Class Sphingosine 1-Phosphate Receptor Modulator for the Treatment of Ulcerative Colitis.
    Choi D; Stewart AP; Bhat S
    Ann Pharmacother; 2022 May; 56(5):592-599. PubMed ID: 34423657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. P035 Ozanimod for Moderate-to-Severe Ulcerative Colitis: North American Population Results During Induction and Maintenance in the Phase 3 True North Study.
    Hudesman D; Long M; Wolf D; Hanauer S; Ghosh S; Petersen A; Pondel M; Silver M; Cross R; Feagan B
    Am J Gastroenterol; 2021 Dec; 116(Suppl 1):S9. PubMed ID: 37461954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histological Outcomes and Predictive Value of Faecal Markers in Moderately to Severely Active Ulcerative Colitis Patients Receiving Infliximab.
    Magro F; Lopes SI; Lopes J; Portela F; Cotter J; Lopes S; Moreira MJ; Lago P; Peixe P; Albuquerque A; Rodrigues S; Silva MR; Monteiro P; Lopes C; Monteiro L; Macedo G; Veloso L; Camila C; Afonso J; Geboes K; Carneiro F;
    J Crohns Colitis; 2016 Dec; 10(12):1407-1416. PubMed ID: 27226417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 study.
    Croft NM; Faubion WA; Kugathasan S; Kierkus J; Ruemmele FM; Shimizu T; Mostafa NM; Venetucci M; Finney-Hayward T; Sanchez Gonzalez Y; Bereswill M; Lazar A; Turner D
    Lancet Gastroenterol Hepatol; 2021 Aug; 6(8):616-627. PubMed ID: 34153231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ozanimod-exposed Patients with Ulcerative Colitis Undergoing Total Colectomy Exhibit Unique Lymph Node Histological Changes.
    Cohen NA; Weber CR; Cheng JX; Choi D; Garcia NM; Choi NK; Rubin DT
    J Crohns Colitis; 2024 Apr; 18(4):638-641. PubMed ID: 37879626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. P037 Effect of Ozanimod Treatment and Discontinuation on Absolute Lymphocyte Count in Moderate-to-Severe Ulcerative Colitis: Results from a Phase 3 Trial.
    Colombel JF; D'Haens G; Irving P; Petersen A; Chitkara D; Marta C; Chen T; Charles L; Danese S; Ghosh S
    Am J Gastroenterol; 2021 Dec; 116(Suppl 1):S9. PubMed ID: 37461956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on ozanimod for ulcerative colitis.
    Antonelli EK; Del Sordo R; Morelli O; Villanacci V; Bassotti G
    Drugs Today (Barc); 2022 Jul; 58(7):351-367. PubMed ID: 35851870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.